No connection

Search Results

SERA vs TCRX

SERA
Sera Prognostics, Inc.
BEARISH
Price
$2.30
Market Cap
$90.0M
Sector
Healthcare
AI Confidence
85%
TCRX
TScan Therapeutics, Inc.
BEARISH
Price
$1.43
Market Cap
$85.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
SERA
--
TCRX
--
Forward P/E
SERA
-3.36
TCRX
-1.86
P/B Ratio
SERA
1.19
TCRX
0.66
P/S Ratio
SERA
1111.49
TCRX
8.32
EV/EBITDA
SERA
-1.49
TCRX
-0.18

Profitability

Gross Margin
SERA
-102.47%
TCRX
0.0%
Operating Margin
SERA
-89540.0%
TCRX
-851.5%
Profit Margin
SERA
0.0%
TCRX
0.0%
ROE
SERA
-51.83%
TCRX
-71.28%
ROA
SERA
-26.15%
TCRX
-27.88%

Growth

Revenue Growth
SERA
-58.3%
TCRX
286.0%
Earnings Growth
SERA
--
TCRX
--

Financial Health

Debt/Equity
SERA
0.03
TCRX
0.76
Current Ratio
SERA
1.69
TCRX
8.41
Quick Ratio
SERA
1.62
TCRX
8.15

Dividends

Dividend Yield
SERA
--
TCRX
--
Payout Ratio
SERA
0.0%
TCRX
0.0%

AI Verdict

SERA BEARISH

SERA presents a contradictory profile with a stable Piotroski F-Score of 6/9 but catastrophic operational metrics. While the balance sheet remains lean with very low debt (D/E 0.03) and adequate liquidity, the company is experiencing a severe revenue collapse (-58.3% YoY) and negative gross margins (-102.47%), indicating that the cost of producing its services exceeds the revenue generated. The extreme Price-to-Sales ratio (1111.49) and aggressive insider selling suggest a lack of confidence in the current business model, rendering the single analyst's 'strong buy' rating highly speculative.

Strengths
Low leverage with a Debt/Equity ratio of 0.03
Stable short-term liquidity (Current Ratio 1.69)
Piotroski F-Score of 6/9 indicates stable financial health relative to its own history
Risks
Severe revenue contraction (-58.3% YoY and Q/Q)
Negative gross margins (-102.47%) indicating a non-viable cost structure
Extreme valuation relative to sales (P/S 1111.49)
TCRX BEARISH

TCRX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 8.41, this is offset by a catastrophic operating margin of -851.50% and a 5-year price decline of 86.4%. The stock is currently a speculative binary play, where a massive disconnect exists between the fundamental health (extremely poor) and analyst price targets ($6.00).

Strengths
Exceptionally high liquidity (Current Ratio 8.41)
Significant YoY revenue growth of 286%
Recent trend of beating EPS estimates (3/4 last quarters)
Risks
Zero Piotroski F-Score indicating systemic financial weakness
Extreme operational inefficiency (Operating Margin -851.50%)
Negative ROE of -71.28% showing rapid equity erosion

Compare Another Pair

SERA vs TCRX: Head-to-Head Comparison

This page compares Sera Prognostics, Inc. (SERA) and TScan Therapeutics, Inc. (TCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile